Free Trial
NASDAQ:CRDL

Cardiol Therapeutics Q3 2023 Earnings Report

Cardiol Therapeutics logo
$1.08 -0.01 (-0.92%)
Closing price 04:00 PM Eastern
Extended Trading
$1.08 -0.01 (-0.46%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiol Therapeutics EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.09
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Cardiol Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cardiol Therapeutics Announcement Details

Quarter
Q3 2023
Time
After Market Closes
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
10:30AM ET

Upcoming Earnings

Cardiol Therapeutics' Q2 2025 earnings is scheduled for Thursday, November 13, 2025

Earnings Documents

Cardiol Therapeutics Earnings Headlines

What is HC Wainwright's Estimate for CRDL FY2028 Earnings?
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
Cardiol Therapeutics Analyst Ratings
Cardiol Therapeutics Analyst Ratings
See More Cardiol Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiol Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiol Therapeutics and other key companies, straight to your email.

About Cardiol Therapeutics

Cardiol Therapeutics (NASDAQ:CRDL), a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

View Cardiol Therapeutics Profile

More Earnings Resources from MarketBeat